Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.84), $0.23 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $523.1 million versus the consensus estimate of $503.13 million.

GUIDANCE:

Exact Sciences sees FY2022 revenue of $2.025-2.042 billion, versus the consensus of $2.01 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.